Table 1 Outcomes
Primary outcomes | Definition | Measure |
|---|---|---|
Viral suppression | HIV viral load <200 copies/ml | HIV viral load <200 copies/ml time-averaged over 3, 6, and 12 months post baseline |
Secondary outcomes | Definition | Measure |
Initiation of MOUD | Receiving prescription and taking first dose of buprenorphine, naltrexone, or methadone | Positive UDS for buprenorphine, naltrexone, or methadone at study follow-up visit after MOUD is prescribed |
HCV cure | Achieving 12-week sustained virologic response | HCV treatment initiated resulting in negative HCV RNA at 12 weeks post treatment completion |
Cost-effectiveness | Cost per unit of a desired outcome (e.g., cost per viral suppression; cost per HCV cure) | Incremental cost-effectiveness ratios (ICERs) over 3, 6, and 12 months post baseline. |